Renal denervation prevents subclinical atrial fibrillation in patients with hypertensive heart disease: Randomized, sham-controlled trial
- 30 June 2022
- journal article
- research article
- Published by Elsevier in Heart Rhythm
- Vol. 19 (11) , 1765-1773
Abstract
No abstract availableKeywords
Funding Information
- Novartis
- Deutsche Gesellschaft für Kardiologie-Herz und Kreislaufforschung.
- Medtronic
- Servier
- Boehringer Ingelheim
- Deutsche Forschungsgemeinschaft (SFB TRR219)
- Merck
- Deutsche Herzstiftung
- AstraZeneca
- Bayer
- Daiichi-Sankyo
This publication has 21 references indexed in Scilit:
- Continuous monitoring after atrial fibrillation ablation: the LINQ AF studyEP Europace, 2018
- Detection of new atrial fibrillation in patients with cardiac implanted electronic devices and factors associated with transition to higher device-detected atrial fibrillation burdenHeart Rhythm, 2018
- Patients with atrial fibrillation and coronary artery disease – Double troubleAdvances in Medical Sciences, 2018
- Hypertension and Atrial FibrillationCirculation Research, 2018
- Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trialThe Lancet, 2017
- Renal sympathetic denervation improves rate control in patients with symptomatic persistent atrial fibrillation and hypertensionActa Cardiologica, 2016
- Catheter-Based Renal Denervation Reduces Atrial Nerve Sprouting and Complexity of Atrial Fibrillation in GoatsCirculation: Arrhythmia and Electrophysiology, 2015
- Inflammation and the pathogenesis of atrial fibrillationNature Reviews Cardiology, 2015
- Predictors of blood pressure response in the SYMPLICITY HTN-3 trialEuropean Heart Journal, 2014
- Subclinical Atrial Fibrillation and the Risk of StrokeNew England Journal of Medicine, 2012